Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

(2021) Justin F Gainor et al.   LANCET ONCOLOGY

State-of-the-Art Strategies for Targeting RET-Dependent Cancers

(2020) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Advances in Targeting RET-Dependent Cancers

(2020) Vivek Subbiah et al.   Cancer Discovery

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues

(2020) Massimo Santoro et al.   Genes

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

(2020) Lori J. Wirth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers

(2018) Vivek Subbiah et al.   Cancer Discovery

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors

(2018) Vivek Subbiah et al.   CANCER RESEARCH

Novel rearrangements involving the RET gene in papillary thyroid carcinoma

(2018) Julia Isabelle Staubitz et al.   Cancer Genetics

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

(2016) Shumei Kato et al.   CLINICAL CANCER RESEARCH

Targeting FGFR Signaling in Cancer

(2015) M. Touat et al.   CLINICAL CANCER RESEARCH

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

(2015) Samuel A. Wells et al.   THYROID

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

(2014) Marcia S Brose et al.   LANCET

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

(2013) Manuela Schmidinger   EJC SUPPLEMENTS

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

(2013) Frauke Bentzien et al.   THYROID

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2

(2012) SM Wagner et al.   Clinics

RET/PTCrearrangement is prevalent in follicular Hürthle cell carcinomas

(2012) Margriet M de Vries et al.   HISTOPATHOLOGY

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

Genetic Alterations in Medullary Thyroid Cancer: Diagnostic and Prognostic Markers

(2011) A. Taccaliti et al.   CURRENT GENOMICS

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Medullary thyroid carcinoma: The third most common thyroid cancer reviewed

(2010) MICHAEL STAMATAKOS et al.   Oncology Letters

Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study

(2007) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM